RISK ASSESSMENT OF DEVELOPING TYPE 2 DIABETES MELLITUS IN PATIENT ON ANTIHYPERTENSIVE MEDICATION

 

Table No. 2 Clinical characteristics of Losartan+HCTZ group at base line & end of study

Characteristics

At base line

end of study

P value

Number of subject

22

22


BMI (kg/m2 )

22.18±0.4050

22.36±0.3397

0.8961ns

Blood Pressure

Systolic BP

129.81±1.22

127.81±0.9662

0.2061ns

Diastolic BP

88.09±1.017

86.72±0.8275

0.3043ns

Blood examination

Blood glucose(mg/dl)

91.36±1.137

89.40±0.7227

0.1542ns

Total cholesterol(mg/dl)

169.66±2.75

169.27±2.75

0.9213ns

Triglyceride(mg/dl)

90.39±3.56

91.05±3.59

0.8962ns

HDL cholesterol(mg/dl)

45.98±1.704

46.25±1.603

0.9087ns

VLDL

18.065±0.7113

17.44±1.027

0.9039ns

LDL

101.44±4.27

104.88±1.639

0.7269ns

· mean±SEM
· *** significant value
· ns non significant

Table No. 3 Clinical characteristics of Losartan+HCTZ Male at base line & end of study

Characteristics

Male (base line)

Male (end of study)

p value

Number of subject

19

19


BMI(kg/m2)

22.44±0.4427

22.36±0.3397

0.9792ns

Blood pressure

Systolic BP

129.78±1.25

127.47±0.8765

0.1387ns

Diastolic BP

88.21±1.176

86.63±0.8793

0.2895ns

Blood examination

Blood glucose (mg/dl)

90.63±1.19

89±0.6882

0.2431ns

Total cholesterol (mg/dl)

171.59±2.926

171.20±2.914

0.9247ns

Triglyceride (mg/dl)

90.28±4.055

91.14±4.068

0.8825ns

HDL Cholesterol (mg/dl)

46.62±1.92

46.83±1.82

0.9368ns

VLDL

18.04±0.8094

18.20±0.8118

0.8901ns

LDL

106.97±1.653

106.17±1.648

0.7331ns

· mean±SEM
· *** significant value
· ns non significant

Table No. 4 Clinical characteristics of Losartan+HCTZ Female at base line & end of study

Characteristics

Female (base line)

Female(end of study)

p value

Number of subject

3

3


BMI(kg/m2)

21.31±0.8313

21.72±0.7554

0.7336ns

Blood Pressure




Systolic BP mmHG

130±5.033

130±5.033

> 0.9999ns

Diastolic BP mmHG

87.33±0.6667

87.33±2.906

> 0.9999ns

Blood examination




Blood glucose (mg/dl)

96±2.51

92±3.05

0.3694ns

Total cholesterol (mg/dl)

157.42±3.025

157.07±3.78

0.9459ns

Triglyceride (mg/dl)

91.06±6.35

90.51±7.15

0.9574ns

HDL cholesterol (mg/dl)

41.93±1.434

42.56±0.6533

0.7069ns

VLDL

18.20±1.268

18.09±1.431

0.9569ns

LDL

97.28±3.102

96.406±3.011

0.8492ns

·  mean±SEM
· *** significant value
· ns non significan

Table No. 5 Clinical characteristics of Atenolol group at base line & end of study

Characteristics

At base line

end of study

P value

Number of subject

8

8


BMI(kg/m2)

22.30±0.4010

22.28±0.4951

0.9754ns

Blood Pressure

Systolic BP mmHG

132.5±1.76

130.5±1.296

 0.3761

Diastolic BP mmHG

88.75±1.065

89.5±1.35

> 0.9999

Blood examination

Blood glucose(mg/dl)

99.375±0.7545

99.87±1.469

0.0014***

Total cholesterol(mg/dl)

181.79±4.19

181.35±4.27

0.9425ns

Triglyceride(mg/dl)

101.04±4.968

100.58±4.791

0.9478ns

HDL cholesterol(mg/dl)

50.02±2.708

50.16±2.41

0.9679ns

VLDL

20.20±2.809

20.11±0.9584

0.9482ns

LDL

111.58±2.55

111.07±2.55

0.8930ns

· mean±SEM
· *** significant value
· ns non significant

Table No.6 Clinical characteristics of Atenolol Male at base line & end of study

Characteristics

Male (base line)

Male (end of study)

P value

Number of subjects

6

6


BMI(kg/m2)

22.155±0.4584

22.55±0.5198

0.5797ns

Blood pressure

Systolic BP

131.66±2.15

130.33±1.74

0.6410ns

Diastolic BP

88±1.26

88.66±1.606

0.7510ns

Blood examination

Blood glucose (mg/dl)

98.16±0.7032

103.5±1.45

0.0080***

Total Cholesterol (mg/dl)

179.18±4.975

178.54±5.043

0.9296ns

Triglyceride (mg/dl)

98.57±5.917

98.06±5.68

0.9513ns

HDL Cholesterol (mg/dl)

48.91±2.55


Pages

FIND MORE ARTICLES